Navigation Links
OxThera startar klinisk studie inom Primär Hyperoxaluri
Date:1/8/2014

STOCKHOLM, January 8, 2014 /PRNewswire/ --

OxThera AB, ett Stockholmsbaserat privat biofarmaceutiskt bolag, meddelar idag att det har startat en klinisk studie inom Primär Hyperoxaluri.  Offentliggörandet stärker ytterligare företagets position som ledare i att utveckla terapier för behandling av hyperoxaluri, en svår sjukdom som leder till njurskador och njurkollaps, om den inte behandlas.

"Vi är mycket glada att meddela att vi har startat vår konfirmerande kliniska studie inom Primär Hyperoxaluri", säger Elisabeth Lindner, VD för OxThera. "Vi är övertygade om att vår nya Oxabact® -produkt har potential att hjälpa patienter med denna svåra sjukdom", fortsätter Elisabeth Lindner.

Den placebokontrollerade studien, OC5-DB-01, utförs på 7 kliniker i tre länder och kommer att inkludera totalt 24 patienter. Resultatet väntas efter sommaren. Oxabact® är en oral produkt som utgörs av högkoncentrerade frystorkade levande bakterier (Oxalobacter formigenes), som administreras i kapslar. Kapslarna är designade för att leverera produkten i tunntarmen, där den så kallade enteriska elimineringen av oxalat initieras. En komplett utvecklingsplan för behandling av patienter som lider av Primär Hyperoxaluri med Oxabact®, har implementerats.

Primär Hyperoxaluri (PH) är en sällsynt autosomal recessiv sjukdom som leder till markant höjda nivåer av endogent oxalat i plasma och urin. Höga nivåer av oxalat ger njurskador och förkalkning av njurarna. Om sjukdomen inte behandlas, kan den orsaka njurkollaps och prematur död. Det finns idag ett stort behov av en fungerande medicinsk behandling för PH. I nuläget är d
'/>"/>

SOURCE OxThera AB
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OxThera coordonne le projet Elimox du 7e PC - 2,19 millions EUR dédiés au développement dun médicament pour traiter lhyperoxalurie
2. OxThera stärker patentportfölj för särläkemedel - Primär hyperoxaluri
3. OxThera stärkt sein Patentportfolio für primäre Hyperoxalurie, eine seltene Krankheit
4. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
5. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
6. RNL BIO har anmält en fas II/III klinisk prövning till KFDA för en behandling av cerebral pares med autologa stamceller framställda från fettvävnad
7. ideaPoint Inc. präsentiert Multi-Sponsor-Portal für Forscheranfragen an fünf globale Studiensponsoren bezüglich Zugang zu Daten aus klinischen Studien
8. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
9. Berg startet bisher erste klinische Stratified-Medicine-Studie zur Untersuchung des Krebsstoffwechsels solider Tumoren
10. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
11. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... ADHD Therapeutics to 2020 - Broadened ... to Drive Market Growth despite Patent ... ADHD Therapeutics to ...
(Date:8/28/2014)... Aug. 28, 2014  Critical Process Filtration, Inc. ... today announces the expansion of their Technical Services ... Filtration now offers customers and potential customers services ... filter failure analyses (even for competitor filters) and ... hallmark services of system benchmarking and cost/performance optimization. ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
...  In conjunction with its first quarter 2012 earnings release (expected to be ... CVD ) is pleased to invite you to listen to its ... on Thursday, May 3, 2012 at 9:00 a.m. ET. , ... and Slide Presentation , , , , When: , , , ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/28/2014)... greater amounts of yellow pigment in your eyes could ... conditions, a new study reports. In a laboratory ... order to test the distance vision of people with ... in their eyes. The volunteers had widely varying ... nutrients lutein and zeaxanthin, according to the researchers, led ...
(Date:8/28/2014)... GreenRushReview.com, a website dedicated to ... “Video” section located at http://www.greenrushreview.com/category/videos/ , which ... cannabis companies in video format. In the site’s ... news clips, interviews, and other short videos discussing ... the videos can also be found on the ...
(Date:8/28/2014)... Alexandria, VA (PRWEB) August 28, 2014 ... Foundation) will interview Stephen Isaacs, the chairperson, president and ... the Foundation’s Meet the Mesothelioma Experts live ... Foundation’s executive director and mesothelioma expert nurse practitioner, ... the interview will be Aduro BioTech’s experimental therapy for ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider of prediabetes ... help clients and online readers send out summer healthfully ... Ashley developed variations of Roasted Veggie Pizza , ... PreDiabetes Centers Roasted Veggie Pizza recipe is made with ... a cheese substitute–ideal for people who are lactose intolerant ...
(Date:8/28/2014)... 2014 veEDIS Clinical Systems, LLC ... System (EDIS), in Lawrence Medical Center, located in ... to document patient care, veEDIS is a key ... well as the authorized, confidential exchange of patient ... veEDIS technology, designed in accordance with clinical workflows ...
Breaking Medicine News(10 mins):Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3
... COPD or chronic obstructive pulmonary disease is a ... // and is associated with severe emphysema or ... can reduce the mortality rate and number of ... study conducted by researchers from the University of ...
... say transmission of genital herpes to others is the ... study shows //the drug valacyclovir may significantly reduce the ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ...
... change the way doctors treat certain prostate cancer patients.The ... cancer patient are grade, PSA level and pathologic stage. ... the Gleason grading system or a Gleason score (GS). ... cancer is seven. In a new study, researchers look ...
... A new study shows the drug valacyclovir may significantly ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ... contagious. Participants with herpes were given ...
... since it interferes with eating and drinking. Children are ... the importance of maintaining// their normal fluid intake despite ... tonsillectomy procedure using less energy than the standard electrocautery ... ,During a tonsillectomy using the electrocautery method, a ...
... by researchers say it is a misconception to believe ... housebound people.// ,Researchers examined 150 children and ... vitamin D. Among the participants, all African-American, East African, ... as were all patients younger than 30. Five patients ...
Cached Medicine News:
... GV is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average = ... hyaluronate. Healon GV contains 14 mg/mL ... a physiological sodium chloride-phosphate buffer (pH ...
... PROVISC ophthalmic viscosurgical device ... is characterized by high molecular ... surface tension. It provides excellent ... and is easily removed. It ...
... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
Medicine Products: